Skip to main navigation Skip to search Skip to main content

Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)

  • Rebecca J Moon
  • , Jean-Yves Reginster
  • , Nasser M Al-Daghri
  • , Jotheeswaran A Thiyagarajan
  • , Charlotte Beaudart
  • , Olivier Bruyère
  • , Nansa Burlet
  • , Manju Chandran
  • , Mario Coelho da Silva
  • , Philip G Conaghan
  • , Willard H Dere
  • , Adolfo Diez-Perez
  • , Peyman Hadji
  • , Philippe Halbout
  • , Mickaël Hiligsmann
  • , John A Kanis
  • , Eugene V McCloskey
  • , Sif Ormarsdottir
  • , Daniel Prieto-Alhambra
  • , Régis P Radermecker
  • René Rizzoli, Yousef Al-Saleh, Stuart L Silverman, Lee S Simon, Friederike Thomasius, Tjeerd van Staa, Andrea Laslop, Cyrus Cooper, Nicholas C Harvey
  • University of Southampton
  • University of Liege
  • King Saud University
  • World Health Organization (WHO)
  • Singapore General Hospital Pte Ltd
  • Universidade de Lisboa
  • University of Leeds
  • University of Utah
  • Universitat Autonoma de Barcelona
  • Instituto de Salud Carlos III
  • International Osteoporosis Foundation (IOF) (Formerly Known As European Foundation for Osteoporosis & Bone Disease)
  • Maastricht University
  • Australian Catholic University
  • The University of Sheffield
  • Icelandic Medicines Agency
  • Oxford University
  • Medizinische Universitat Wien Medical University Vienna
  • Hôpitaux Universitaire de Genève
  • King Saud bin Abdulaziz University for Health Sciences
  • Cedars-Sinai Medical Center
  • SDG LLC
  • Austrian Medicines and Medical Devices Agency

Research output: Contribution to journal › Review article › peer-review

Abstract

UNLABELLED: This narrative review summarises the recommendations of a Working Group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) for the conduct and reporting of real-world evidence studies with a focus on osteoporosis research.

PURPOSE: Vast amounts of data are routinely generated at every healthcare contact and activity, and there is increasing recognition that these real-world data can be analysed to generate scientific evidence. Real-world evidence (RWE) is increasingly used to delineate the natural history of disease, assess real-life drug effectiveness, understand adverse events and in health economic analysis. The aim of this work was to understand the benefits and limitations of this type of data and outline approaches to ensure that transparent and high-quality evidence is generated.

METHODS: A ESCEO Working Group was convened in December 2022 to discuss the applicability of RWE to osteoporosis research and approaches to best practice.

RESULTS: This narrative review summarises the agreed recommendations for the conduct and reporting of RWE studies with a focus on osteoporosis research.

CONCLUSIONS: It is imperative that research using real-world data is conducted to the highest standards with close attention to limitations and biases of these data, and with transparency at all stages of study design, data acquisition and curation, analysis and reporting to increase the trustworthiness of RWE study findings.

Keywords

  • Humans
  • Osteoporosis
  • Osteoarthritis/therapy
  • Musculoskeletal Diseases/therapy
  • Societies, Medical

Fingerprint

Dive into the research topics of 'Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)'. Together they form a unique fingerprint.

Cite this